PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2004 June; 5(2): 1–8.
Published online 2004 March 9. doi:  10.1208/pt050225
PMCID: PMC2750460

Effect of potassium chloride and cationic drug on swelling, erosion and release from κ-carrageenan matrices

Abstract

The basic objective of this work was to study the effect of model cationic drug metformin HCl on swelling and erosion and, in turn, the release of KCl and drug itself, from the κ-carrageenan matrices. Water uptake by the matrix up to 2 hours was found to increase with KCl concentration from the plain matrix. Erosion was not affected by concentration of KCl. Incorporation of drug favors water uptake, but in presence of KCl it was found to be reduced. Drugcontaining matrices have shown higher release of KCl as compared with plain batches. Drug release was retarded as KCl concentration increased up to 5%, above which the reduced cohesivity of the matrix caused increase in drug release.

Keywords: κ-carrageenan, cationic drug, swelling, erosion, KCl

Full Text

The Full Text of this article is available as a PDF (457K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Brazel CS, Peppas NA. Modelling of drug release from swellable polymers. Eur J Pharm Biopharm. 2000;49:47–58. doi: 10.1016/S0939-6411(99)00058-2. [PubMed] [Cross Ref]
2. Guo JH, Skinner GW, Harcum WW, Barnum PE. Pharmaceutical application of naturally occurring water-soluble polymers. PSTT. 1998;1:254–261.
3. Gupta VK, Hariharan M, Wheately TA, Price JC. Controlled-release tablets from carrageenans: effect of formulation, storage and dissolution factors. Eur J Pharm Biopharm. 2001;51:241–248. doi: 10.1016/S0939-6411(01)00135-7. [PubMed] [Cross Ref]
4. Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985;60:110–111. [PubMed]
5. FMC . Marine Colloids Carrageenan, General Technology. Philadelphia, PA: FMC Corporation; 1993.
6. Hariharan M, Wheatley TA, Price JC. Controlled-release tablet matrices from carrageenans: compression and dissolution studies. Pharm Dev Technol. 1997;2:383–393. doi: 10.3109/10837459709022637. [PubMed] [Cross Ref]
7. Masaaki S, Chikanori Y, Kazuhiro H, et al. Structural change of κ-carrageenan gel near sol-gel transition point. Physica B. 1998;243:999–1001. doi: 10.1016/S0921-4526(97)00779-5. [Cross Ref]
8. van de Velde F, Peppelman A, Rollema HS, Tromp RH. On the structure of κτ-hybrid carrageenans. Carbohydr Res. 2001;331:271–283. doi: 10.1016/S0008-6215(01)00054-4. [PubMed] [Cross Ref]
9. Yuguchi Y, Thuy TTT, Urakawa H, Kajiwara K. Structural characteristic of carrageenan gels: temperature and concentration dependence. Journal. 2002;16:515–522.
10. Picker KM. Carrageenans used for tabletting and controlled release. Proceedings of the 2nd World Meeting. May 25–28, 1998; Paris, France.
11. Picker KM. Matrix tablets of carrageenans. I. A compaction study. Drug Dev Ind Pharm. 1999;25:329–337. doi: 10.1081/DDC-100102178. [PubMed] [Cross Ref]
12. Jovetic S, Beeftink HH, Tramper J, Marinelli F. Diffusion of (de)acylated antibiotic A40926 in alginate and carrageenan beads with or without cells and/or soybean meal. Enzyme and Microbiology Technology. 2001;28:510–514. doi: 10.1016/S0141-0229(01)00292-7. [PubMed] [Cross Ref]
13. Sipahigil O, Dortune B. Preparation and in vitro evaluation of verapamil HCl and ibuprofen containing carrageenan beads. Int J Pharm. 2001;228:119–128. doi: 10.1016/S0378-5173(01)00814-6. [PubMed] [Cross Ref]
14. Hoffinan AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev. 2002;54:3–12. doi: 10.1016/S0169-409X(01)00239-3. [PubMed] [Cross Ref]
15. Rochas C, Rinaudo M. Activity coefficient of counterions and conformation in κ-carrageenan system. Biopolymers. 1980;19:1675–1687. doi: 10.1002/bip.1980.360190911. [Cross Ref]
16. Morris ER, Rees DA, Norto IT, Goodall DM. Cation-specific aggregation of carrageenan helices: domain model of polymer gel structure. J Mol Biol. 1980;138:349–362. doi: 10.1016/0022-2836(80)90291-0. [PubMed] [Cross Ref]
17. Schmidt AG, Wartewigand S, Picker KM. Potential of carrageenan to protect drugs from polymorphic transformation. Eur J Pharm Biopharm. 2003;56:101–110. doi: 10.1016/S0939-6411(03)00037-7. [PubMed] [Cross Ref]
18. Picker KM. Matrix tablets of Carrageenans. II. Release behavior and effect of added cations. Drug Dev Ind Pharm. 1999;25:339–346. doi: 10.1081/DDC-100102179. [PubMed] [Cross Ref]
19. Sjöberg H, Persson S, Caram-Lelham N. How interactions between drugs and agarose-carrageenan hydrogels influence the simultaneous transport of drugs. J Control Release. 1999;59:391–400. doi: 10.1016/S0168-3659(99)00013-9. [PubMed] [Cross Ref]
20. Roy DS, Rohera BD. Comparative evaluation of rate of hydration and matrix erosion of HEC and HPC and study of drug release from their matrices. Eur J Pharm Sci. 2002;16:193–199. doi: 10.1016/S0928-0987(02)00103-3. [PubMed] [Cross Ref]
21. Vergnaud JM. Liquid transport controlled release process in polymeric materials: applications to oral dosage forms. Int J Pharm. 1993;90:89–94. doi: 10.1016/0378-5173(93)90145-6. [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists